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A second DNA binding site in human BRCA2
promotes homologous recombination
Catharina von Nicolai1, Åsa Ehle´n1, Charlotte Martin1, Xiaodong Zhang2 & Aura Carreira1
BRCA2 tumour-suppressor protein is well known for its role in DNA repair by homologous
recombination (HR); assisting the loading of RAD51 recombinase at DNA double-strand
breaks. This function is executed by the C-terminal DNA binding domain (CTD) which binds
single-stranded (ss)DNA, and the BRC repeats, which bind RAD51 and modulate its assembly
onto ssDNA. Paradoxically, analysis of cells resistant to DNA damaging agents missing the
CTD restore HR proﬁciency, suggesting another domain may take over its function. Here, we
identify a region in the N terminus of BRCA2 that exhibits DNA binding activity (NTD) and
provide evidence for NTD promoting RAD51-mediated HR. A missense variant detected in
breast cancer patients located in the NTD impairs HR stimulation on dsDNA/ssDNA junction
containing substrates. These ﬁndings shed light on the function of the N terminus of BRCA2
and have implications for the evaluation of breast cancer variants.
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B
RCA2-deﬁcient tumour cells accumulate chromosomal
abnormalities and this genome instability is thought to
have a causative role in BRCA2-associated cancer1,2.
BRCA2 maintains genome integrity through its function
in the repair of DNA double-strand breaks by homologous
recombination (HR)3–5. In this process, the recombination
protein RAD51 and BRCA2, together with other factors,
perform a reaction in which a damaged chromatid pairs
with the intact sister resulting in the exchange of genetic
information from the latter to the former. The DNA binding
activity of BRCA2 is integral to its HR function as it facilitates
the loading of the recombination protein RAD51 at DNA
breaks. This function is ensured by the DNA binding domain
located at the carboxy (C) terminus of the protein (CTD)6.
Yet, cells resistant to DNA damage devoid of the entire CTD can
still function in HR7,8 suggesting that additional functional
domains in BRCA2 could take over CTD’s function. To test
this hypothesis, we used protein secondary structure prediction
tools (see Supplementary Methods) and identiﬁed a zinc ﬁnger
(zf)-PARP like domain containing residues predicted to bind
DNA in the amino (N) terminus of BRCA2 that are conserved in
mammals (Supplementary Fig. 1). This analysis prompted us to
test the functional relevance of this domain.
We reveal a DNA binding domain in the N terminus
of BRCA2 that can stimulate RAD51-mediated homologous
recombination and is mutated in breast cancer patients.
Results
The N terminus of BRCA2 binds DNA. We expressed and
puriﬁed from human cells several fragments of the N terminus of
BRCA2; BRCA2T1 (aa 1–250), BRCA2T2 (aa 250–500), BRCA2LT2
(aa 1–500) and BRCA2LT3 (aa 1–750; Supplementary Fig. 1c,d)
and tested their DNA binding activity by Electrophoretic Mobility
Shift Assay (EMSA). Incubation of a ssDNA homopolymer,
dT40 and increasing concentrations of BRCA2T2, BRCA2LT2 or
BRCA2LT3, but not BRCA2T1, generated a slower mobility species
corresponding to DNA–protein complexes. Their DNA binding
activity reached 20–40% of ssDNA–protein complex at 300 nM
(Fig. 1a,b). These results suggest that the region comprising
BRCA2T2 binds to ssDNA.
To further validate the DNA binding activity of this region, we
examined the partition of BRCA2T2 compared with BRCA2T1
between biotinylated ssDNA (dT80) immobilized on streptavidin
magnetic beads challenged with excess dT40 ssDNA. This
experiment conﬁrmed our results; only BRCA2T2 and not
BRCA2T1 was titrated out by adding excess dT40 indicating that
BRCA2T2 binds speciﬁcally to DNA (Supplementary Fig. 2a,b).
Collectively, these results indicate that the N-terminal region of
BRCA2 binds DNA and that the region of aa 250–500 of BRCA2
(BRCA2T2) comprising the putative zf-PARP domain is sufﬁcient
for this activity.
BRCA2T2 binds with stronger afﬁnity to DNA than the CTD.
To examine the possible function and speciﬁcity of the DNA
binding domain identiﬁed in the N-terminal region (NTD), we
compared the DNA binding afﬁnity of BRCA2T2 with that of the
CTD (aa 2,474–3,190; Fig. 2a) for different DNA substrates.
As described for the mouse CTD6, human CTD bound to all
DNA forms except dsDNA (Fig. 2b–f). Remarkably, at the
attainable concentration (1.5mM), BRCA2T2 showed higher yield
of DNA–protein complexes than the CTD for all DNA substrates
tested (Fig. 2b–f). In contrast to the CTD, BRCA2T2 also bound to
dsDNA resulting in a yield of protein–dsDNA complex ofB40%
at 1.5 mM, similar to that of ssDNA (Fig. 2c, Supplementary
Fig. 3a,b). Moreover, BRCA2T2 exhibited signiﬁcantly higher
yield of DNA–protein complexes when bound to gapped DNA
compared with the CTD, reaching aB40-fold difference at 1 mM
of protein concentration (Fig. 2f).
In addition, we compared the DNA binding activity of
BRCA2T2 with that of full-length BRCA2. As expected, BRCA2
bound readily to ssDNA (Supplementary Fig. 4b) and to a lesser
extent to dsDNA (Supplementary Fig. 4c) to levels comparable
to those reported previously3. BRCA2T2 bound ssDNA or dsDNA
to the same extent as BRCA2 but the concentration to reach the
same amount of product was B100 times higher suggesting
that the two DNA binding domains, CTD and NTD, display
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Figure 1 | The N terminus of BRCA2 binds DNA. (a) EMSA showing BRCA2LT3, BRCA2LT2, BRCA2T1 and BRCA2T2 binding to ssDNA (dT40).
(b) Quantiﬁcation of a. Error bars, s.d. (n¼ 3).
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Figure 2 | BRCA2T2 binds to different DNA substrates and with stronger afﬁnity than CTD. (a) M size markers. (1) SDS–PAGE showing puriﬁed CTD
(5mg) loaded in a 4–15% acrylamide gel. (2) Western blot of the gel shown with an antibody against the His tag of the CTD and an antibody speciﬁc
to DSS1 protein co-puriﬁed with it. (b) EMSA and quantiﬁcation comparing the binding of BRCA2T2 and CTD to ssDNA (167mer). (c) dsDNA (40mer),
(d) 3’ ssDNA overhang, (e) 5’ ssDNA overhang, (f) gapped DNA. Error bars, s.d. (n¼ 3).
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cooperative afﬁnity for ssDNA in the context of the full-length
protein. It is also possible that the isolated fragments display a
different conformation than when comprised in the full-length
protein explaining their lower afﬁnity for DNA.
These results indicate that BRCA2T2 exhibits an increased
relative afﬁnity or higher complex stability for all DNA substrates
compared with the CTD, especially those containing dsDNA or a
dsDNA/ssDNA junction.
C315S breast cancer variant impairs NTD dsDNA binding.
NTD comprises a putative zf-fold, which is usually stabilized by
cysteine and histidine residues9,10. To ﬁnd out the residues
important for DNA binding, we mutated three of the cysteines
present in the domain (Supplementary Fig. 1) and tested their
effect on DNA binding. We chose to mutate two cysteines that
have been found substituted for serine in breast cancer patients
(C315S, C341S) but for which the clinical relevance is still
unknown (Breast Cancer Information Core and BRCAshare
databases). The third one is a substitution of C279 to alanine
(Fig. 3a). Single or double mutations were introduced in the
BRCA2T2 fragment and puriﬁed (Supplementary Fig. 5a). None
of the single or double mutations affected signiﬁcantly the ssDNA
binding activity of BRCA2T2 (Fig. 3b,c and Supplementary
Fig. 5b,c). We next tested the effect of the single or the
double mutations on dsDNA binding. Interestingly, the single
substitution C315S reduced the dsDNA binding by B6.5 fold,
whereas the other single mutations did not or very mildly affected
it (Fig. 3d,e). Accordingly, the double mutations containing the
C315S substitution potentiated this effect (Fig. 3f,g). Moreover,
C315S mutation mildly reduced the ability of BRCA2T2 to bind a
3’overhang ssDNA by B1.7 fold (Fig. 3h,i).
These results imply that C315S, a missense mutation frequently
observed in breast cancer, highly impairs the interaction of
BRCA2 with dsDNA.
NTD can stimulate RAD51-mediated DNA strand exchange.
A fusion peptide containing a single BRC repeat of BRCA2 and
the CTD or a BRC repeat and the ssDNA binding domain of
replication protein-A (RPA), are able to enhance RAD51
recombination activity11,12. In the recombination process,
replication RPA coats ﬁrst the ssDNA to remove secondary
structure, an interaction that is inhibitory for RAD51 assembly
onto ssDNA due to the stronger afﬁnity of RPA for ssDNA13,14.
Mediator proteins like BRCA2 counteract the inhibitory effect of
RPA. In view of the DNA binding activity exhibited by BRCA2T2,
we assessed whether a fusion of BRCA2T2 and BRC4,
BRCA2BRC4-T2 (Supplementary Fig. 6a), could promote the
DNA strand exchange activity of RAD51.
Optimal RAD51 (220nM) and RPA (25 nM) concentrations
based on RAD51 and RPA titration experiments (Supplementary
Fig. 6b) were used in an in vitro short oligonucleotide
DNA strand exchange assay3. RPA was incubated ﬁrst with a
3’overhang ssDNA substrate (scheme in Fig. 4a), and as expected,
RAD51 recombination activity was compromised (Fig. 4a,
third lane). Importantly, BRCA2BRC4-T2 was able to overcome
the inhibition by RPA and stimulate the reaction by B6-fold
at 300 nM protein concentration reaching similar levels of
stimulation of BRCA2 although at 10 times higher concentration
(Fig. 4b). Strikingly, BRCA2T2 alone also stimulated the reaction to
a similar extent than BRCA2BRC4-T2 (Fig. 4d and Supplementary
Fig. 6c) though it does not interact directly with RAD51
(Supplementary Fig. 6d) or RPA (Supplementary Fig. 6e).
These results suggest that at saturating concentration of
RAD51 and with a short DNA sequence, the binding of BRCA2T2
to DNA is sufﬁcient to facilitate RAD51 recombination. Another
explanation for this result could be that BRCA2T2 counteracts the
competition of RPA for ssDNA allowing assembly of RAD51
onto the ssDNA (Fig. 4c,d). Consistent with this idea, BRCA2T2
did not stimulate the DNA strand exchange reaction in the
absence of RPA (Supplementary Fig. 7a,b). In contrast, the fusion
peptide BRCA2BRC4-T2 showed a stimulatory effect of B1.8 fold,
comparable to that of full-length BRCA2 (Supplementary
Fig. 7c,d). Similar to mouse CTD6, human CTD did not
stimulate the DNA strand exchange reaction in the absence
of RPA (Supplementary Fig. 7a,b) but stimulated the
RPA-containing reaction by B3-fold at 10 mM (Fig. 4c,d).
In conclusion, BRCA2BRC4-T2, BRCA2T2 and, to a much lesser
extent, the CTD can all promote the RPA-dependent DNA strand
exchange activity of RAD51. It is important to note that the
concentration of BRCA2BRC4-T2 needed to reach the same
amount of product formation as full-length BRCA2 is 10 times
higher. These results can be explained by the fact that (i) the NTD
alone binds with lower afﬁnity to DNA than full-length BRCA2
(Supplementary Fig. 4b,c); (ii) the NTD is missing the DNA
binding activity and stimulatory action of the CTD which is
present in the full-length protein.
dsDNA binding is required to stimulate HR at dsDNA/ssDNA.
Considering the binding of BRCA2T2 to duplex DNA-containing
structures, we reasoned that this activity might be required for
the stimulation of DNA strand exchange when using dsDNA-
containing substrates. We conducted a DNA strand exchange
reaction using a 3’ overhang ssDNA in the presence of the single
mutant BRCA2T2 C315S with reduced dsDNA binding activity.
Indeed, BRCA2T2 C315S decreased the stimulation of DNA
strand exchange activity of RAD51 by B3-fold compared with
BRCA2T2, an effect that was further potentiated by the double
mutation C279A/C315S (Fig. 4e,f). To conﬁrm that the defective
stimulation of DNA strand exchange is due to the inability of
BRCA2T2 C315S to bind dsDNA and not to a faulty folding due
to the mutation, we conducted the same reaction using a ssDNA
substrate. Indeed, C315S mutation stimulated the ssDNA-based
strand exchange of RAD51 as much as BRCA2T2 (Fig. 4g,h) or
full-length BRCA2 (Supplementary Fig. 8), suggesting that the
single substitution C315S affects the stimulation of DNA strand
exchange with the 3’ ssDNA overhang substrate because of its
defective dsDNA binding activity.
On the basis of the results with both DNA substrates, we can
presume that BRCA2T2 stimulate RAD51-mediated DNA strand
exchange in two ways: (1) Physically blocking the binding of
RAD51 to dsDNA and (2) Competing with RPA for ssDNA. Only
the second would be acting in the case of C315S, which would
explain why there is normal stimulation of DNA strand exchange
when using a ssDNA substrate, whereas it is reduced in the case
of the tailed DNA.
Discussion
A bias towards ssDNA/dsDNA junctions has been described for
the functional homologues of BRCA2, the bacterial RecFOR, and
its orthologue in U. maydis, Brh2, but not for human BRCA2
(ref. 3). Although the helix-turn-helix motif present in the CTD
suggested dsDNA-binding activity6, the interaction with this type
of substrate has not been detected for CTD6,15. Our ﬁndings
suggest that NTD speciﬁcally contributes the binding of
BRCA2 to dsDNA allowing the association with dsDNA/
ssDNA junctions.
Combining our results with previous ﬁndings3–5,16–18 we
propose a model whereby in the context of a ssDNA/dsDNA
junction-containing lesion (Supplementary Fig. 9); NTD binds at
the dsDNA/ssDNA junction ﬁrst, facilitating the loading and
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Figure 3 | Cysteine residues located in the putative zf-PARP-like domain and mutated in breast cancer patients affect the dsDNA binding activity of
BRCA2T2. (a) amino-acid sequence comprised in the putative zf-PARP-like domain deﬁned by SMART showing the mutated cysteine residues. The ones
found in breast cancer patients are highlighted in red. (b) Quantiﬁcation of EMSA displayed in Supplementary Fig. 5b, (c) showing the binding of BRCA2T2,
the indicated single mutants (c), and the double mutants to ssDNA. (d) EMSA showing the binding of BRCA2T2 and the indicated single mutants (e), and
the double mutants to dsDNA. (f) Quantiﬁcation of d. (g) Quantiﬁcation of e. (h) EMSA showing the binding of BRCA2T2 and BRCA2 C315S to 3’ overhang
ssDNA. (i) Quantiﬁcation of h. Error bars, s.d. (n¼ 3).
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stabilization of RAD51 nucleoprotein ﬁlament onto RPA-coated
ssDNA by the BRC repeats18. CTD binds along the ssDNA
and actively facilitates the displacement of RPA19 allowing
multiple nucleation events and ﬁlament extension of
RAD51. These activities enhance the subsequent steps of
homologous recombination.
It is possible that both NTD and CTD are required for
assembly of RAD51 onto ssDNA in the context of full-length
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BRCA2. Alternatively, the two DNA binding sites may act on
different substrates depending on the DNA damage encountered.
How the two DNA binding modules of BRCA2 are coordinated
in vivo warrants further investigation.
Methods
Expression and puriﬁcation of proteins. All BRCA2 N-terminal expression
constructs containing the sequence coding for BRCA2 amino acids 1–250 (BRCA2T1),
251–500 (BRCA2T2), 1–500 (BRCA2LT2) and 1–750 (BRCA2LT3) were ampliﬁed by
PCR from a 2 MBP-BRCA2 phCMV1 vector3 and cloned by restriction digest with
XhoI and NotI into a phCMV1 vector containing an N-terminal 2MBP tag with
two nuclear localization signals (NLS) downstream the tag.
Point mutations were introduced using QuikChange II site-directed mutagenesis
kit (Agilent) and veriﬁed by sequencing. BRCA2BRC4-T2 fusion construct was
generated by HIFI Gibson Assembly (NEB) in the phCMV1 2MBP 2 NLS vector.
All the constructs mentioned above including the vector containing the MBP
tag and the NLS used as control were ampliﬁed with NucleoBond Xtra Midi kit
(Macherey Nagel) and used for transfection.
Ten 150mm conﬂuent plates of HEK293 cells were transiently transfected with
TurboFect (Thermo Scientiﬁc) following the manufacturer’s speciﬁcations and
harvested 30 h post transfection. After lysis with 50mM HEPES (pH 7.5), 250mM
NaCl, 5mM EDTA, 1% NP40, 1mM DTT, 1mM PMSF and EDTA-free Protease
Inhibitor Cocktail (Roche), the suspension was incubated for 3 h with amylose
resin (NEB). The 2 MBP tagged BRCA2 fragments were eluted with 10mM
maltose. The eluates were further puriﬁed with Bio-Rex 70 cation-exchange resin
(Bio-Rad) by NaCl step elution (50mM HEPES pH 7.5, 0.5mM EDTA,
10% glycerol, 1mM PMSF, 1mM DTT and 250mM, 450mM or 1M NaCl).
The size and purity of the BRCA2 fragments were veriﬁed by loading the ﬁnal
fractions on a SDS–PAGE (polyacrylamide gel electrophoresis) gel and detecting
the MBP tag by western Blot (mAB R29, Invitrogen).
The protein concentration of the nuclease-free fractions was determined using
NanoOrange Protein Quantitation Kit (Thermo Fisher) and by density
determination in SDS–PAGE gel using BSA as a standard.
The C-terminal DNA binding domain (aa 2,474–3,190) of human BRCA2
(CTD) was cloned into pET28 6His SUMO vector. pCDF DSS1 expression vector
was generated by HIFI Gibson Assembly (NEB) from a pFASTBAC Dual-DSS1
vector (kind gift from R.B. Jensen). The CTD was co-expressed with DSS1 to
ensure stability of the protein. E.coli BL21 DE3 pISO Dscb cells (kind gift of
A. el Marjou) were transformed and grown at 37 C in 7 litres of Terriﬁc Broth and
induced with 0.5% arabinose and 1mM IPTG overnight at optical density 2. The
cells were collected in 20mM Tris-HCl pH 8, 300mM NaCl, 10% glycerol, 0.5mM
EDTA, 5mM b-mercaptoethanol, 1 Protease Inhibitor Cocktail EDTA-free
(Roche), 10mM MgCl2, 1 DNase, 0.5mgml 1 Lysozyme (Sigma-Aldrich) and
the suspension was lysed by disintegration at 1.7 kbar.
The His-tagged protein was incubated with Protino Ni-NTA agarose
(Macherey Nagel) and eluted with 200mM imidazole. After dialysis overnight
against 20mM Tris-HCl pH 8, 100mM NaCl, 10% glycerol, 0.5mM EDTA, 5mM
b-mercaptoethanol, the eluate was loaded onto a 5ml HiTrap Heparin HP
column (GE) and eluted using a continuous NaCl gradient (100-1M NaCl) in the
same buffer.
The protein was visualized on a 7.5% SDS gel and the protein concentration was
determined by Bradford assay.
To generate EGFP-MBP-BRCA2, one MBP-tag of a phCMV1 2 MBP-BRCA2
vector (kind gift from S.C. Kowalczykowski) was substituted by an EGFP tag
ampliﬁed by PCR from a pEGFP-C1 vector (Invitrogen) and cloned by restriction
digest with KpnI. EGFP-MBP-tagged BRCA2 was puriﬁed as described above for the
protein fragments. The concentration was determined by NanoOrange Protein
Quantitation Kit (ThermoFisher Scientiﬁc) and adjusted by loading it on a gel,
subtracting the contributions from contaminants or truncated BRCA2 polypeptide.
Human RAD51 was cloned into pCDF 6his SUMO vector. E. coli BL21 BRL were
transformed and grown in 7 l of Terriﬁc Broth at 37 C in a fermenter. At optical
density¼ 1, the temperature was decreased to 20 C and protein expression was
induced with 0.5mM IPTG overnight at 700 RPM. The cells were harvested by
centrifugation at 9,000g for 10min at 4 C and resuspended in 1 PBS, 350mM
NaCl, 20mM imidazole, 10% glycerol, 0.5mgml 1 lysozyme, 1 Protease Inhibitor
Cocktail (Roche), 0.5mM PMSF, 10mM MgCl2, DNase and extracted using a
disintegrator at 1.8kbar and collected by centrifugation at 48,000g for 30min. The His-
tagged protein was incubated with Protino Ni-NTA agarose (Macherey Nagel) and
washed with 20mM Tris-HCl pH 8.0, 20mM imidazole, 10% glycerol, 100mM NaCl,
5mM b-mercaptoethanol. The His-tag was cleaved by incubating the resin with
0.4mgml 1 SUMO Protease at 4 C overnight. The supernatant from the Ni-NTA
resin containing the cleaved RAD51 protein was then loaded onto a 5ml HiTrap
Heparin HP chromatography column (GE) in 20mM Tris-HCl pH 8, 10% glycerol,
100mM NaCl and 5mM b-mercaptoethanol. RAD51 protein was eluted using a
continuous NaCl gradient (100mM-2M NaCl) in the same buffer. The eluate was
dialysed against RAD51 storage buffer (20mM Tris HCl pH 8, 50mM KCl, 0.5mM
EDTA, 1mM DTT, 10% glycerol, 0.5mM PMSF) and visualized on a 7.5%
SDS–PAGE gel stained with Coomassie Brilliant Blue. The protein concentration was
determined by Bradford assay.
His-tagged RPA was a kind gift from M. Modesti (IGH, Marseille).
BRCA2T2-BRC4, fusion construct was generated by Gibson HIFI assembly (NEB)
in the phCMV1-EGFP-MBP 2NLS BRC4 vector background (pAC138).
After puriﬁcation, all proteins and fragments were aliquoted, frozen in liquid
nitrogen and stored at  80 C.
Antibodies. Antibodies were obtained from the following sources: Anti-BRCA2
(1:2,000; OP95-100UG, EMD Milipore), anti-DSS1 (1:500; sc-28848, Santa Cruz
Biotechnology), anti-MBP (1:5,000; 33–5,100, Invitrogen), anti-His (1:1,000;
PEP-156P Eurogentec).
Uncropped western blots for Fig. 2, and Supplementary Figs 1 and 4 are shown
in Supplementary Fig. 10.
Electrophoretic mobility shift assay. DNA substrates were purchased
PAGE-puriﬁed from MWG Euroﬁns. The sequence of the oligonucleotides used for
these assays are included in Supplementary Table 1. The ssDNA substrates used in
EMSA were oAC379 and oAC423 32P labelled at the 5’-end. To generate the
dsDNA substrates, oAC405 was 32P labelled at the 5’-end and annealed in a
1:1 molar ratio to oAC406. The 3’ and 5’ overhang substrates were produced by
annealing 32P-labelled oAC490 (42mer  3’) to oAC423 (167mer) or oAC403
(42mer 5’) to oAC423 in a 1:1 molar ratio, respectively. oAC423, oAC403 and
oAC490 were annealed in a 1:1:1 ratio to produce the gapped DNA substrate.
The proteins were incubated at the indicated concentrations with 0.2 mM
nucleotides 32P-labelled DNA substrates for 1 h at 37 C in EMSA reaction buffer
(25mM Tris Acetate pH 7.5, 1mM DTT, 1mM MgCl2, 2mM CaCl2). The
protein–DNA complexes were resolved on 6% native polyacrylamide gels in
1 TAE buffer (40mM Tris Acetate, 0.5mM EDTA) at 70V for 75min. The gels
were dried and analysed with a Typhoon PhosphorImager (Amersham
Biosciences) using Image Quant software (GE Healthcare). In all EMSAs except for
the ones shown in Supplementary Fig. 4, the ratio of DNA–protein complexes was
calculated as the percentage of bound DNA compared with the free DNA. Because
full-length BRCA2 binding to DNA results in fast and slow complexes that result in
a smear, the percentage of protein–DNA complexes in Supplementary Fig. 4 was
quantiﬁed as the free radiolabelled DNA remaining in a given lane relative to the
protein-free lane. The protein-free lane deﬁned the value of 0% complex.
DNA strand exchange assay. The 3’tail DNA substrate and dsDNA donor
template were generated as described for the EMSA except that only the dsDNA
was radiolabelled. RPA (25 nM) or storage buffer was pre-incubated with 4 nM
molecules of 3’tail DNA or ssDNA for 5min at 37 C. Then, RAD51 (220 nM)
alone or with the indicated concentrations of BRCA2 were added to the mix and
incubated for 5min at 37 C in a buffer containing 25mM Tris Acetate pH 8.0,
1mM DTT, 2mM ATP, 1mM MgCl2, 2mM CaCl2, 0.1mgml 1 BSA. The
reaction was started by adding 4 nM molecules of the donor template dsDNA
(oAC405 and oAC406 1:1) and the mix was further incubated for 30min at 37 C.
The reaction was stopped by incubation with 0.25% SDS and 0.5mgml 1
Proteinase K for 10min. The samples were loaded on a 6% polyacrylamide gel and
migrated at 70 V for 75min. The gels were dried and analysed with a Typhoon
PhosphorImager (Amersham Biosciences) using Image Quant software
(GE Healthcare). The percentage of DNA strand exchange product was calculated
as labelled product divided by total labelled input DNA in each lane.
Afﬁnity pull-down with amylose beads. Before pull-down assays, amylose resin
(NEB) was equilibrated with binding buffer: 50mM HEPES (pH 7.5), 250mM
NaCl, 0.5mM EDTA and 1mM DTT. Puriﬁed 2XMBP-BRCA2BRC4-T2 or 2xMBP-
BRCA2T2 proteins (1.25 mg) were incubated with 1 mg puriﬁed RAD51 for 30min
at 37 C and then batch bound to 30 ml of amylose resin for 1 h at 4 C. The
complexes were washed with binding buffer (50mM HEPES (pH 7.5), 250mM
NaCl, 0.5mM EDTA and 1mM DTT) containing 1% NP-40. Proteins were eluted
with 30ml 10mM maltose in binding buffer, resuspended in 1 SDS sample
buffer, heated at 54 C for 5min and loaded onto a 4–15% gradient SDS–PAGE gel.
The gels were stained with SYPRO Orange.
Data availability. All the relevant data are available from the authors upon
request.
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